OAS3 is upregulated in ccRCC and promotes tumor progression by mediating the infiltration of immune cells in the TME. OAS3 represents a promising therapeutic target for enhancing the antitumor effects of immune checkpoint inhibitors.
Xinxin Liao (Thu,) studied this question.